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The generation of a report of findings and a conclusion for an imaging study is a fundamental process in the diagnostic
work-up of cancer patients and plays a critical role in treatment decisions. It is therefore important that cancer imaging
specialists understand the needs of referring clinicians and can perform this process in a methodical manner.
Surprisingly, in contrast to the literature regarding the outcomes of imaging, education regarding the methods that
underpin the generation of a report and how to communicate the findings cogently to referring clinicians is rather
sparse. In an upcoming series of articles that will appear in in Cancer Imaging, experts in various modalities will detail
their approach to reporting scans in particular disease settings. In this article some personal perspectives on the
process of reporting scans will be detailed as a guide to what will be elaborated in the “Master Class Series”.
Introduction
Working, as I do, in a busy cancer imaging department
that is actively involved in training of fellows and visiting
imaging specialists, I have become acutely aware of how
many basic processes involved in displaying, reviewing
and interpreting scans I take for granted. Preceding the
images even arriving at the workstation for reporting,
decisions have been made about patient preparation and
study acquisition that influence the material available for
review. Most large departments have established proto-
cols to standardise these technical aspects of imaging,
and default settings come preloaded by manufacturers of
imaging equipment or DICOM viewing software. How-
ever, with all these steps successfully negotiated, special-
ist review of the acquired images is required for an
informative report to be generated. Without specific
teaching, trainees develop their own method of review-
ing images and a personal style of reporting, often as-
similating what they observe during reporting sessions
with more senior members of their local team. Mean-
while, most formal teaching focuses on the identification
and description of disease and ignores the procedure of
reading scans and communicating the findings.
Similarly, while a great deal of literature exists about
typical disease findings, often by way of atlas-based
teaching, and regarding the accuracy or impact of im-
aging studies in clinical practice, there is relatively little
guidance on those, seemingly, more mundane processes
of image interpretation, including windowing of scans
and the order in which image sets are reviewed. Often
the technical aspects of scanning are highly abbreviated
to meet word limits set by print journals or simply omit-
ted as being irrelevant to the focus of the paper. Yet like
a golfer who wants to improve his or her swing by focus-
sing sequentially on the grip, the position of the feet,
head alignment, backswing, point of contact and follow-
through, dissecting the process of cancer imaging study
acquisition, interpretation and reporting is vital to im-
proving the end product. For us, an accurate study that
succinctly answers the clinical question posed by the re-
ferring doctor is our hole-in-one.
What better way to dissect these processes than to ask
an expert coach? With Cancer Imaging being the official
journal of the International Cancer Imaging Society, we
have the luxury of access to recognised leaders in the
field of oncological imaging with expertise that spans
many modalities and diseases. Our Section Editors re-
flect and co-opt this expertise in their daily work. These
same experts frequently run Master Classes as part of
the annual teaching course of the International Cancer
Imaging Society or during satellite meetings. It, there-
fore, seemed to me that this invaluable experiential
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resource should be made available to our readership. Ac-
cordingly, I have commissioned our Editorial Board to
either write themselves, or to invite respected colleagues
to write, a series of articles that don’t reflect a traditional
review of the literature pertaining to their areas of inter-
est but rather to crystallise their own personal approach
to reading scans in particular cancer settings. These will
focus on how they display, manipulate, and sequence
images to assemble the pertinent findings required to
reach a conclusion to a clinical question. Since these re-
views will necessarily reflect highly personal approaches,
moulded by experience and their own influencers, they
won’t necessarily be the same as other experts might
recommend. However, they will hopefully provide some-
one entering the field a foundation on which they can
build their own framework. We hope that this will act in
print as a surrogate of a hands-on master class and
stimulate mentors and teachers to discuss their own ap-
proach with their trainees.
How I read cancer imaging studies
While I will leave it largely to my esteemed colleagues to
write reviews on specific subjects pertinent to their areas
of interest, I would like to share my own general ap-
proach to reporting of cancer imaging studies. My
modus operandi has developed over the past quarter of a
century and reflects the positive influences of many in-
spiring mentors but also lessons learnt from my own er-
rors. I can assure you that there have been many
opportunities for cancer to find me out. It is a harsh
critic! Its often remorseless progression unmasks the
subtle and not-so-subtle abnormality that one over-
looks, prodding one always to read more sensitively
until one is equally chastised by the false-positive result
that has committed a patient to unnecessary interven-
tion or treatment. I have learnt that more harm comes
to patients from overcalling than ignoring subtle abnor-
malities [1].
Having trained first as a physician, my internal medi-
cine background strongly influenced a problem-oriented
approach. In my initial studies around the diagnostic
process in cardiology, I was also highly influenced by
Bayesian principles [2]. I think that these two factors
have stood me, and I hope my patients, well when ap-
plied to the field of cancer imaging.
When I was a young doctor doing a country rotation, I
was fortunate to work with a very wise and excellent
family physician. He told me that there are three steps
to being a good doctor. The first is to take a history
from the patient until they have told you everything that
they need to say. The second is to do an examination
until you have found everything that you need to know.
The third is to come up with a diagnosis that you can
both live with.
I’ve tried to apply these same principles to reporting of
scans. My first step is formulation of the clinical ques-
tion being posed. It is somewhat depressing how seldom
the precise reason for a request is actually articulated on
the written request form. Divining what the question is
can involve review of the patient’s clinical notes, ques-
tioning the patient directly, perhaps via a standardised
questionnaire, or, in need, by calling the referring doctor.
Another of my former mentors told me that the most
useful diagnostic tool in radiology is the telephone. To
formulate in your own mind a question to be addressed
informs a systematic approach to the next phases of the
reporting process but also requires a significant know-
ledge base. I sometimes think that the most important
part of training a young imaging specialist to interpret
oncological studies is not so much to recognise abnor-
malities but rather to understand oncological principles
and the questions that are important to clinicians man-
aging patients with cancer. These include an under-
standing of basic treatment paradigms in a given disease.
In particular, when loco-regional therapies such as sur-
gery or radiotherapy are appropriate, the need to exclude
distant metastatic disease becomes pivotal. My first
question to myself and to my fellows when looking at a
scan is, “What is the question here?”
Next comes the examination. Just as we were taught
as medical students, general inspection should precede
more detailed and specific eliciting of signs of disease.
As with clinical examination, optimal viewing requires
good lighting. For imaging, this involves appropriate
thresholding or windowing of images, which is a process
that varies according to modality and its application.
This process will be detailed in the specific articles in
this series. In PET and general nuclear medicine we have
long had the luxury of having an overview of the scan in
the form of a maximum intensity projection (MIP)
image, or of a whole body planar scan in the anterior
and posterior projections. These images provide a gestalt
of the sites of abnormality. Often within milliseconds of
these images being viewed, a diagnosis can be made re-
garding the presence or absence of abnormality and,
based on pattern recognition, of the likely diagnosis. Al-
though MIP image generation is becoming more preva-
lent in anatomical imaging, it is generally more difficult
to gain such a rapid overview of the whole body for CT
and MRI. For tomographic imaging, the next thing that I
do is to scroll through the coronal image set. Although
tomographic imaging historically developed as an axial
scanning technique [3], the body actually makes much
more sense when viewed in the coronal plane as most
tubular structures run vertically or transversely in this
plane rather than being rounded. I will return to the sig-
nificance of this later in discussion of ‘Rod’s Rules’. Any
apparent abnormalities observed on scrolling through
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these images are then triangulated and viewed in the sa-
gittal and transaxial planes. For PET/CT, I look first at
the stand-alone PET images and then at the CT images,
first on the soft tissue window, then on bone windows
and finally on lung windows. For assessing the liver, fur-
ther windowing to optimise lesion visualisation on non-
contrast CT may be appropriate. Although I have noted
a tendency for neophytes in hybrid imaging to devolve
immediately to simply scrolling through the fused trans-
axial images and then correlating any abnormality found
on the stand-alone CT image, I have found that my sys-
tematic approach provides greater sensitivity and specifi-
city in identifying abnormalities and recognising normal
variants. I actually see the fused images as a marketing
tool! If an appropriate colour scale is utilised, the result-
ing fused images provide an intuitive representation of
pathological findings that clinicians have readily em-
braced. Further discussion of the use of colour scales in
imaging will be included in later articles in this series.
By the time I’ve done this evaluation, I have generally
formulated in my mind how I am going to address the
clinical question. For example, if the primary purpose of
the scan is to stage a known malignancy, I adopt a for-
mat based on the TNM staging system. Focussing first
on the primary tumour, the qualities of the lesion are de-
scribed. For PET this involves a description of the inten-
sity and homogeneity of uptake and pertinent localising
details followed by the associated radiologic features of
relevance, including size, outline, calcification, necrosis
and relation to key anatomical landmarks that help to
define T-stage. At this point, I will also mention any dir-
ect complications or confounding factors. These might
include effusions, collapse or features of infection.
Thereafter, nodal disease, if present, is described from
proximal to distal stations along with the qualitative fea-
tures and, if pertinent, quantitative parameters of inten-
sity and size. The description of stage is completed by
identifying any suspected distant metastases, grouped by
organ system. As part of this description I mention, par-
ticularly, those that might be at risk of complications,
such as cord compression, fracture or obstruction. I also
indicate pertinent negative findings. For example, if a
given cancer has a predilection to spread to a particular
organ, for example, ocular melanoma to the liver or
prostate cancer to bone, I indicate that these sites are
not involved. This helps to reassure the referring clin-
ician that I am both aware of metastatic patterns and
that I have carefully assessed these sites. Further, abnor-
malities that might be confused as being metastases but
have some characteristics that allow assignment of a be-
nign aetiology are mentioned. In PET, lung granulomas
and adrenal incidentalomas are probably the most com-
mon. Importantly, I detail any additional findings that
might be relevant to the management of the patient. For
example, the presence of vascular disease, particularly
coronary artery calcification in a patient who might be
being considered for major surgery or active inflamma-
tion in someone who would soon receive chemotherapy,
since these can be a source of septicaemia during any
period of neutropaenia. Finally, I describe any abnormal-
ities or normal variants that are irrelevant to the ques-
tion being addressed. I tell my fellows that at the end of
this description, the reader should be able to imagine
the scan without having the images available. We do,
however, routinely insert representative save screens into
our reports.
The routine is the same but the description differs if
the question relates to therapeutic response, suspected
residual disease or relapse. For these, reference is made
to prior findings, when available with focus on the char-
acteristics, location and associations of sites of residual
abnormality. Again, there is attention to pertinent nega-
tive findings and abnormalities that are the result of
prior treatment rather than the disease itself.
Rod’s rules
A critical part of cancer imaging is the assessment of
whether abnormalities reflect malignancy or are relevant
to the management of the patient. Since benign lesions,
non-oncological pathologies and even second malignan-
cies can co-exist with cancer or develop following suc-
cessful treatment of cancer, being able to provide the
managing clinician with guidance on the likely nature of
abnormalities can be extremely helpful.
Over the years I have developed certain principles that
help me in this process and that I share with all our
trainees. I call them Rod’s Rules.
Rod’s rule number 1
Cancers grow like cities; radially until they meet a phys-
ical barrier, which they spread along, or are given a road
to follow.
Thus, most cancers, if unrestrained grow into spheres
and thus appear rounded in each orthogonal projection. If
constrained by an anatomical boundary, like the pleura or
muscularis layer of the gastrointestinal tract, they will
spread along this boundary. In the gut, this sub-mucosal
spread leads to tumours appearing fusiform. Once a
tumour breaches a physical barrier, and enters a new
space, it again adopts a radial growth pattern that leads to
the presence of lobulation. Alternatively if it enters a
structure where it can follow a line of low resistance, it
does so. The most obvious paths are lymphatics, leading
to spiculation, but others include the pleural and periton-
eal spaces and bloods vessels, particularly veins, which are
easy to tumours to invade than more muscular arteries.
As tumours extend into spaces they become more plaque-
like whereas within a vessel they become tubular.
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Inflammatory processes are less respectful of physical bar-
riers and tend to rely on direct permeation or passage
through tissue via pathogenic portals of entry.
Rod’s rule number 2
Just as children generally resemble their parents, metas-
tases generally bear significant resemblance to the char-
acteristics of the primary lesion and if they don’t, only
genetic testing can confirm their lineage.
Although heterogeneity is increasingly being recog-
nised as a feature of the evolution of cancers, generally
there are more similarities between the primary cancer
and its metastases than there are between the cancer
and normal tissues. This is reflected in their imaging
phenotype. For example, mucinous primary tumours will
generally give rise to mucinous metastases. On PET, the
presence of an intensely FDG-avid primary significantly
diminishes the likelihood that an enlarged adrenal with-
out significant tracer uptake represents a metastasis.
With the increasing use of hybrid anatomical and mo-
lecular imaging, discordance between the interpretation
of abnormalities on one component of the scan and the
other may need biopsy to determine the nature of the
abnormality. Alternatively, different molecular imaging
signals between lesions that might otherwise be inter-
preted as being part of the same process can reflect syn-
chronous or metachronous primaries. Differentiating
between a metastatic process and occurrence of a
tumour that might still be treated curatively can have
significant positive implications for patient care and is
not nearly as uncommon as one might think [4].
Rod’s rule number 3
As security agencies have learnt, if members of a crowd are
behaving differently from the rest of the crowd, they are
probably not part of it and need to be watched. Presumed
metastases that are not responding in parallel with other
lesions to treatment might reflect a different disease.
Mixed responses in cancer are relatively uncommon.
Typically all deposits respond, or not, relatively consist-
ently to treatment, either regressing or progressing over
time. When a lesion behaves differently from the rest, it
is likely to represent either a different disease process or
a resistant clone of cells. Accordingly, characterising
such lesions by biopsy or molecular imaging can pro-
vide insight into their nature. We commonly see trans-
formed lymphoma responding rapidly and completely
to immuno-chemotherapy, whereas more indolent
clones of low-grade follicular lymphoma can shrug off
this treatment, remaining enlarged on CT. Heterogen-
eity of response is more prevalent with targeted therap-
ies. Cells lacking the target will remain effectively
untreated and will, if it is their nature, grow despite
dramatic responses in lesions that contain exclusively
or dominantly cells that express the target of the thera-
peutic agent. Mixed responses are less common with
conventional cytotoxic therapies and therefore differen-
tial responses more commonly represent a different
pathological process.
When assessing therapeutic response, it is important is
important to not only compare the current scan with
that immediately preceding it, but also to review prior
scans. Lack of response in a lesion that had been stable
prior treatment increases the likelihood of a benign aeti-
ology. Conversely, by providing a greater interval be-
tween scans, it is sometimes possible to appreciate more
subtle progression and regression of disease than can be
evaluated from two scans that are separated by only a
few weeks or months.
Formulating a conclusion to a cancer imaging
report
The conclusion of an imaging report should not simply
be a reiteration of the findings. The first and most im-
portant aspect of a conclusion is, in my opinion, to dir-
ectly address the clinical question. This should also
recognise the level of knowledge and interest of the re-
cipient. While any medically trained person should easily
understand the conclusion, it should also be tailored to
the training of the recipient. For example, a report re-
garding prostate cancer findings might be different if
being sent to a surgeon compared to a radiation oncolo-
gist. Ideally, the level of confidence regarding a given set
of findings should be communicated rather than simply
a list of differential diagnoses. When the results are truly
equivocal, this should be accompanied by suggestions on
how a diagnosis might be reached, especially if alterna-
tive imaging might help. If appropriate, given the relative
oncological expertise of the referring clinician and the
imaging specialist, management guidance could be given.
In areas of oncology in which I have both diagnostic and
therapeutic experience, I am quite comfortable recom-
mending treatment options for patients on the basis of
scan findings. Working in a multidisciplinary environ-
ment, as is increasingly common in oncology, the report
should address issues that might be pertinent to a num-
ber of involved craft groups.
As well as detailing positive findings that justify the
conclusion, any highly pertinent negative findings should
also be articulated. Finally, incidental findings that may
warrant further investigation that might influence fur-
ther management choices, should be detailed.
A final word
I hope that you are looking forward as much as I am to
the guidance of our Editorial Board and their esteemed
colleagues on how to read scans and formulate a report
in their areas of specific expertise.
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